1978 1980 1981 1982 1983 1984

1985 1986 1987 1988 1989 1990

1992 1993 1994 1995 1996 1997

1998 1999 2000 2001 2002 2003

2004 2005 2006 2007 2008

PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.
Oesterling JE, Suman VJ, Zincke H, Bostwick DG.

Mesoblastic nephroma of adulthood. Report of three cases.
Durham JR, Bostwick DG, Farrow GM, Ohorodnik JM.

Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma.
Bostwick DG, Srigley J, Grignon D, Maksem J, Humphrey P, van der Kwast TH, Bose D, Harrison J, Young RH.

Atypical basal cell hyperplasia of the prostate. Immunophenotypic profile and proposed classification of basal cell proliferations.
Devaraj LT, Bostwick DG.

Staging of early prostate cancer: a proposed tumor volume-based prognostic index.
Bostwick DG, Graham SD Jr, Napalkov P, Abrahamsson PA, di Sant'agnese PA, Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, et al.

Workgroup #3: Monitoring effects of treatment for cancer and for benign prostatic hyperplasia.
Jones GW, Smith RA, Batjer JD, Bostwick DG, Corn BW, Guess HA, Hudson MA, Kabalin J, Soloway MS.

Cystosarcoma phyllodes of the seminal vesicle.
Fain JS, Cosnow I, King BF, Zincke H, Bostwick DG.

Architectural patterns of high-grade prostatic intraepithelial neoplasia.
Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS.